RGS9 Activators
RGS9, a crucial regulator in G-protein signaling pathways, is influenced by various chemical compounds that modulate GPCR and related signaling pathways, thereby affecting its functional activity. Forskolin, by elevating cAMP levels, can indirectly enhance RGS9 activity, as RGS9 plays a significant role in terminating G-protein signaling, a process that becomes increasingly important with enhanced GPCR signaling. Isoproterenol, a beta-adrenergic agonist, and Pilocarpine, a muscarinic receptor agonist, both enhance GPCR signaling, thereby increasing the functional demand for RGS9 in regulating G-protein activity. This increased signaling necessitates greater RGS9 activity to maintain the proper regulation of G-protein signaling termination.
Phosphodiesterase type 5 (PDE5) inhibitors like Sildenafil, Vardenafil, Hydrochloride Salt, and Tadalafil, by increasing cGMP levels, can also indirectly modulate GPCR signaling pathways, potentially enhancing RGS9 activity in smooth muscle and visual processing systems. Propranolol, a beta-adrenergic receptor antagonist, and Atropine, a muscarinic receptor antagonist, alter GPCR signaling dynamics, affecting the balance of G-protein signaling and thus influencing RGS9's activity in various physiological systems. Additionally, (S)-(-)-Nicotine and Amphetamine, through their actions on nicotinic acetylcholine receptors and monoamine neurotransmitter systems, respectively, can indirectly enhance RGS9 activity. These compounds modulate neuronal GPCR signaling, altering the dynamics of G-protein signaling in neuronal pathways where RGS9 plays a regulatory role. Collectively, these compounds, through their targeted effects on GPCR and related signaling pathways, synergistically enhance the functional activity of RGS9, highlighting its critical role in the regulation of G-protein-mediated cellular responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Increases cAMP levels, which can indirectly enhance RGS9 activity. RGS9 is involved in the regulation of G-protein signaling, and elevated cAMP levels can lead to enhanced GPCR signaling, subsequently increasing the functional need and activity of RGS9 in its role as a GTPase-activating protein for G-protein alpha subunits. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor, it can indirectly influence RGS9 activity by modulating G-protein-coupled receptor (GPCR) signaling pathways, particularly those involving RhoA and downstream effectors. This modulation can result in altered G-protein signaling dynamics, potentially enhancing the role of RGS9 in GPCR signaling. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
A beta-adrenergic agonist that enhances GPCR signaling, potentially increasing the functional demand for RGS9 in the regulation of G-protein activity. Increased GPCR signaling can lead to a greater need for RGS9's GTPase-activating function to terminate G-protein signaling, thereby enhancing its activity. | ||||||
Pilocarpine | 92-13-7 | sc-479256 | 100 mg | $255.00 | 1 | |
A muscarinic acetylcholine receptor agonist. By stimulating these GPCRs, Pilocarpine can increase the need for RGS9-mediated modulation of G-protein signaling, enhancing the role of RGS9 in terminating G-protein signaling following receptor activation. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Similar to Sildenafil, as a PDE5 inhibitor, it increases cGMP levels. Elevated cGMP levels can indirectly modulate GPCR signaling pathways, potentially enhancing RGS9 activity in processes like smooth muscle relaxation and visual signal transduction. | ||||||
Tadalafil | 171596-29-5 | sc-208412 | 50 mg | $180.00 | 13 | |
Another PDE5 inhibitor, it increases cGMP levels, which can indirectly affect GPCR signaling. This modulation can enhance the activity of RGS9 in relevant signaling pathways, particularly in vascular and visual systems. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
A beta-adrenergic receptor antagonist, which can indirectly influence RGS9 activity by altering GPCR signaling. The modulation of adrenergic signaling can lead to changes in the functional requirements for RGS9 in regulating G-protein signaling, particularly in cardiac and nervous system functions. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $204.00 | 2 | |
A muscarinic receptor antagonist, which can affect the balance of GPCR signaling and thereby indirectly influence the activity of RGS9. By modulating muscarinic signaling, Atropine can alter the demand for RGS9's GTPase-activating function in regulating G-protein signaling. | ||||||